IceCure Medical Ltd (ICCM)
| Market Cap | 35.53M |
| Revenue (ttm) | 3.26M |
| Net Income (ttm) | -14.49M |
| Shares Out | 47.94M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 221,705 |
| Open | 0.716 |
| Previous Close | 0.740 |
| Day's Range | 0.709 - 0.779 |
| 52-Week Range | 0.520 - 1.570 |
| Beta | 2.90 |
| Analysts | Strong Buy |
| Price Target | 2.95 (+298.0%) |
| Earnings Date | Aug 12, 2024 |
About ICCM
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system ... [Read more]
Financial Performance
In 2023, ICCM's revenue was $3.23 million, an increase of 4.67% compared to the previous year's $3.09 million. Losses were -$14.65 million, -13.70% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ICCM stock is "Strong Buy." The 12-month stock price forecast is $2.95, which is an increase of 298.00% from the latest price.
News
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes
CAESAREA, Israel , July 1, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destro...
IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024
Recent insider open-market stock purchases demonstrate continued confidence in the Company CAESAREA, Israel , June 18, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Me...
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function
ICESECRET interim results, as previously announced, demonstrated ProSense® to be safe and effective in treating kidney tumors with 89.5% recurrence-free rate More data is expected in the fourth quarte...
FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan
Demonstrates public health importance of assessing ProSense®'s potential to offer optimal treatment that benefits women with early-stage breast cancer Patients, patient advocacy groups, doctors, and t...
IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024
30% sales growth reflects continued adoption of ProSense® in the U.S. and other global markets Major milestones achieved: - Completion of landmark ICE3 trial for breast cancer - Positive final ICE3 tr...
IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024
CAESAREA, Israel, May 21, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that de...
IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase
CAESAREA, Israel , May 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that d...
Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally
Study published in the peer reviewed journal Breast Cancer Excellent cosmetic outcomes, high degree of patient satisfaction, and improved quality of life post-cryoablation Strategic distribution partn...
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer
Data presentation at highly influential American Society of Breast Surgeons ("ASBrS") Annual Meeting by Dr. Richard Fine wins Scientific Impact Award as voted by breast surgeons President-Elect of th...
IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance
Conference call to be held today at 10:00 am Eastern Time; Focus on U.S. market for ProSense® in breast cancer indication CAESAREA, Israel , April 3, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq:...
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes
Continuous innovation as a global leader in minimally invasive liquid-nitrogen based cryoablation systems CAESAREA, Israel , April 2, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure...
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024
Overview of U.S. Commercial Strategy will be Discussed on Conference Call CAESAREA, Israel , March 27, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer ...
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy
Expects to submit full dataset to the FDA in April for marketing authorization of ProSense® for minimally invasive treatment of early-stage breast cancer Study represents largest cryoablation study of...
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes
Innovating as a global leader in cryoablation technologies, with 42 patents issued and allowed Cryogenic flow control enhances the efficacy and precision of cryoablation procedures CAESAREA, Israel , ...
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference
CAESAREA, Israel , March 7, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that ...
IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024
MRI reveals disappearance of hemorrhagic signal and development of necrotic changes Pain reduced from a median of 7 on a scale of 0 - 10 to a median of 1, with some patients reporting 0 CAESAREA, Is...
Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop
Session conducted by Dr. Rupa Renganathan, who performed India's first breast cancer cryoablation procedure with ProSense®; Expert interview with Dr. Hania Bednarski, who has performed cryoablation br...
Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer
Independent study in women deemed inoperable for breast cancer reports median tumor reduction of 100% at 6 and 12 months following cryoablation CAESAREA, Israel , Feb. 26, 2024 /PRNewswire/ -- IceCure...
IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan
CAESAREA, Israel , Feb. 15, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that ...
U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer
IceCure to submit full 5-year dataset from entire ICE3 study population to the FDA this spring, ahead of previous expectation CAESAREA, Israel , Jan. 30, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NAS...
IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class
IceCure exhibits and provides hands-on demonstrations at SIO 2024 Annual Meeting in California, receiving enthusiastic response from interventional oncologists ICE3 trial data were central to the Brea...
IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation
ProSense® users speaking at the conference about cryoablation included ISVIR President Dr. Suyash Kulkarni, as well as Dr. Shuvro Roy-Choudhury CAESAREA, Israel , Jan. 16, 2024 /PRNewswire/ -- IceCure...
IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
CAESAREA, Israel, Jan. 12, 2024 (GLOBE NEWSWIRE) -- IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), developer of the ProSense® System, a minimally-invasive cryoablation technology th...
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results
U.S. sales continue to increase with 25% jump in ProSense® system and disposable probe sales in 2023 over prior year ICE3 study is set for completion and final data read out CAESAREA, Israel , Jan. 10...
New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response
Independent mouse study conducted at Case Western Reserve University School of Medicine, published in OncoImmunology, builds on body of evidence demonstrating cryoablation can activate the body's natu...